ConductScience.org, home

Comparison · NCT03932240-deaths

Fibrinogen Concentrate (FC) vs Cryoprecipitate: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Fibrinogen Concentrate (FC) vs Cryoprecipitate: deaths from any cause. Trial comparisons, record NCT03932240-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03932240-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.05560.009880.258wilson
Risk in group 20.05560.009880.258wilson
Risk difference, group 1 minus group 20-0.2070.207newcombe hybrid score
Risk ratio, group 1 over group 210.067614.8log
Odds ratio, group 1 over group 210.057717.3log
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Fibrinogen Concentrate (FC)Neonates undergoing elective cardiac surgery requiring cardiopulmonary bypass (CPB) who were randomized to receive platelets and fibrinogen concentrate after separation from bypass.118EG000
Group 2CryoprecipitateNeonates undergoing elective cardiac surgery requiring cardiopulmonary bypass (CPB) who were randomized to receive platelets and cryoprecipitate after separation from bypass.118EG001

Harm

What it counts
Total, all-cause mortality
Time frame
Information on serious and non-serious adverse events was collected beginning at the time consent to participate in the study was given through 7 days post-surgery. Mortality was collected until the participant was discharged from the hospital (up to 150 days).

Source ClinicalTrials.gov

Trial

Title
In Vivo Effects of Fibrinogen Concentrate (FC) Versus Cryoprecipitate on the Neonatal Fibrin Network Structure After Cardiopulmonary Bypass (CPB)
NCT number
NCT03932240
Phases
PHASE3
Conditions
Hemostasis
Interventions
Fibrinogen Concentrate (FC), Cryoprecipitate
Lead sponsor
Emory University
Results first posted
2023-03-20

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03932240-deaths